Special Meeting of Stockholders - Access for Participants by Webcast and Conference Call
Application for Listing on NASDAQ Capital Market
GI Dynamics to Hold Briefing Call and Webcast on
Financial Results for Third Quarter 2014
EndoBarrier® is indicated to treat patients with type 2 diabetes and/or obesity for 12 months.
EndoBarrier® has received regulatory approval and is commercially available for use in select international markets.
EndoBarrier® is not approved for sale in the United States and is considered investigational.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE